A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

• Status: RECRUITING
• Trial end date: 2026-11-01

Summary

The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.

• Phase: PHASE1

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: retatrutide; semaglutide